Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets

This publication has 21 references indexed in Scilit:

• R 68 070: Thromboxane A2 Synthetase Inhibition and Thromboxane A2/Prostaglandin Endoperoxide Receptor Blockade Combined in One Molecule - II. Pharmacological Effects In Vivo and Ex Vivo
  Thrombosis and Haemostasis, 1989
• R 68 070: Thromboxane A2 Synthetase Inhibition and Thromboxane A2/Prostaglandin Endoperoxide Receptor Blockade Combined in One Molecule - I. Biochemical Profile In Vitro
  Thrombosis and Haemostasis, 1989
• Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
  Journal of Clinical Investigation, 1987
• The biochemical pharmacology of thromboxane synthase inhibition in man.
  Circulation, 1985
• Inhibition of platelet-activating-factor-induced human platelet activation by prostaglandin D2. Differential sensitivity of platelet transduction processes and functional responses to inhibition by cyclic AMP
  Biochemical Journal, 1985
• Interaction of stable prostaglandin endoperoxide analogs U46619 and U44069 with human platelet membranes: Coupling of receptors with high-affinity GTPase and adenylate cyclase
  Thrombosis Research, 1985
• Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin
  European Journal of Pharmacology, 1982
• Inhibition of 5-hydroxytryptamine-induced and-amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist
  Inflammation Research, 1982
• INHIBITION OF THROMBOXANE SYNTHETASE DOES NOT NECESSARILY PREVENT PLATELET AGGREGATION
  The Lancet, 1981
• Albumin stabilizes thromboxane A₂
  FEBS Letters, 1977